August 5, 2022

Dear Senator:

On behalf of the Endocrine Society, the world’s largest professional organization of endocrinologists, I am writing to urge your support of the *Inflation Reduction Act*, which will take transformational steps to make insulin more affordable for people living with diabetes by addressing both its cost to patients and price. Endocrine Society members provide care to millions of people across the country with diabetes who rely on insulin to live. This legislation would finally address this longstanding problem, which Congress has examined closely over the last several years. The Endocrine Society is supporting passage of this legislation because it will provide much needed relief to our patients who struggle to afford this life-saving medication.

Last year was the 100th anniversary of the discovery of insulin, and despite this important milestone, insulin remains unaffordable for many who rely on it. The price of insulin nearly tripled between 2002 and 2013. More recently, the list price of insulin nearly doubled between 2012 and 2016. In the United States, more than 7 million people rely on insulin to manage their diabetes. Approximately 283,000 children in the United States have been diagnosed with diabetes, which includes 244,000 living with type 1 diabetes. People who rely on insulin have struggled to afford this medication for many years, but the impacts of inflation have made this issue even more dire due to the rising cost of basic necessities. People with diabetes should not be forced to choose between buying groceries and taking the medication they need to survive.

The Endocrine Society has shared with the Senate [patient stories](#) from around the country illustrating that people with diabetes continue to suffer due to the high price of insulin. We have also offered a spectrum of [policy recommendations](#) over the past few years to make insulin more affordable. We are pleased that the *Inflation Reduction Act* includes provisions to lower the price of insulin and institute a $35 co-pay cap on out-of-pocket costs of insulin. These provisions align with the Society’s policy recommendations on insulin access and affordability and would provide meaningful relief to people with diabetes. This legislation represents a tremendous opportunity to address the high price of insulin and reduce out-of-pocket costs for people who rely on insulin. It’s time for Congress to address this longstanding problem and pass this legislation today. **On behalf of our...**
patients, we urge you to support passage of the Inflation Reduction Act when it is considered in the Senate. People with diabetes cannot wait any longer.

If you have any questions or we can be of any further assistance, please contact Rob Goldsmith, Director of Advocacy and Policy.

Sincerely,

Ursula Kaiser, MD
President
Endocrine Society